Back close
Admissions

The Role of Gefitinib in Patients with Non-small-cell Lung Cancer in India

Publication Type : Scientific reports

Publisher : National Library of Medicine

Source : Indian J Palliat Care. 2013 Jan;19(1):48-53. doi: 10.4103/0973-1075.110237. PMID: 23766595; PMCID: PMC3680839.

Url : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680839/#:~:text=Median%20time%20to%20progression%20was,with%20no%20significant%20side%20effects.

Campus : Kochi

School : School of Medicine

Year : 2013

Abstract : Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor, represents a new treatment option for patients with advanced non-small-cell lung cancer (NSCLC). We analyzed the data of patients who received Gefitinib for NSCLC in a tertiary care center in South India.

Cite this Research Publication : Mehta AA, Jose WM, Pavithran K, Triavadi GS. The Role of Gefitinib in Patients with Non-small-cell Lung Cancer in India. Indian J Palliat Care. 2013 Jan;19(1):48-53. doi: 10.4103/0973-1075.110237. PMID: 23766595; PMCID: PMC3680839.

Admissions Apply Now